SAN DIEGO, March 5, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the Naval Medical Research Center (NMRC) has initiated a Phase 1 human clinical trial of a ...
Vical Incorporated VICL today announced that the Naval Medical Research Center has initiated a Phase 1 human clinical trial of a tetravalent dengue DNA vaccine formulated with the company's Vaxfectin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback